Dr. Myra Finn Wedmid, M.D.
What this data tells you about Dr. Finn Wedmid
Dr. Myra Finn Wedmid is a radiation oncology specialist in Warren, NJ, with 18 years of NPI registration. Based on federal Medicare data, Dr. Finn Wedmid performed 9,044 Medicare services across 3,007 unique beneficiaries.
Between the years covered by Open Payments, Dr. Finn Wedmid received a total of $154 from 2 pharmaceutical and/or device companies across 2 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in radiation oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Finn Wedmid is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| MRI contrast dye injection (gadoterate) Administration of gadoterate meglumine, a contrast agent, in a 0.1 ml dose. |
6,050 | $0 | $1 |
| 3D screening mammography (tomosynthesis) A screening imaging test of the breast using 3D technology to detect potential abnormalities. |
920 | $58 | $200 |
| Screening mammography An X-ray of the breast used to detect breast cancer in women who have no signs or symptoms of the disease. |
916 | $144 | $415 |
| Bone density scan (DEXA) A test that uses low-dose X-rays to measure bone mineral density in the hip, pelvis, and spine. It helps assess bone strength and risk of fractures. |
355 | $43 | $375 |
| Digital breast tomosynthesis (3D mammogram) A specialized imaging test that creates three-dimensional pictures of the breast tissue to help detect abnormalities. |
228 | $45 | $348 |
| Diagnostic mammography of 1 breast An X-ray examination of one breast to evaluate specific breast symptoms or abnormalities. |
167 | $105 | $390 |
| Limited ultrasound of 1 breast A focused ultrasound examination of a single breast to evaluate specific areas of concern. |
150 | $76 | $573 |
| Diagnostic mammography of both breasts | 107 | $132 | $465 |
| Breast biopsy with ultrasound-guided localization device placement This procedure involves taking a tissue sample from a breast growth and placing a marker device to locate it, guided by ultrasound imaging. |
45 | $443 | $2,750 |
| Breast biopsy with localization device using X-ray A procedure to remove a sample of breast tissue for testing, using X-ray guidance to place a device that marks the location of the first growth. |
35 | $409 | $3,250 |
| MRI scan of both breasts A magnetic resonance imaging test that creates detailed pictures of both breasts to help evaluate breast tissue. |
35 | $298 | $2,760 |
| Complete breast ultrasound, 1 breast A complete ultrasound examination of one breast to visualize internal structures. |
25 | $131 | $980 |
| Bone density scan (DEXA) of hip, pelvis, and spine This test measures bone density in the hip, pelvis, and spine to assess bone strength. It also includes an assessment for spine fractures. |
11 | $58 | $350 |
Industry Payment Transparency
Open Payments through 2020 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2020)
All-time payments by company (2018-2020) ›
Associated products mentioned in payments ›
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
5.6 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2020 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Finn Wedmid is a mixed practice specialist, with above-average Medicare volume (top 29% in NJ), with low-engagement industry engagement, with 18 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Finn Wedmid experienced with mri contrast dye injection (gadoterate)?
Does Dr. Finn Wedmid receive payments from pharmaceutical companies?
How do Dr. Finn Wedmid's costs compare to other radiation oncologists in Warren?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology